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ABSTRACT
Anti-angiogenic therapy of solid tumors has until now failed to produce the long 
lasting clinical benefits desired, possibly due to the complexity of the neoangiogenic 
process. Indeed, a prominent role is played by “vasculogenic” or “vascular” 
mimicry (VM), a phenomenon in which aggressive cancer cells form an alternative 
microvascular circulation, independently of endothelial cell angiogenesis. In this 
study we observed, in melanoma patient cell lines having vasculogenic/stem-cell like 
phenotype and in melanoma tumors, the Syndecan-1 co-expression with VM markers, 
such as CD144 and VEGFR-2. We show that melanoma cells lose their ability to form 
tubule-like structures in vitro after blocking Syndecan-1 activity by the specific human 
recombinant antibody, OC-46F2. Moreover, in a human melanoma xenograft model, 
the combined therapy using OC-46F2 and L19-IL2, an immunocytokine specific for the 
tumor angiogenic-associated B-fibronectin isoform(B-FN), led to a complete inhibition 
of tumor growth until day 90 from tumor implantation in 71% of treated mice, with 
statistically significant differences compared to groups treated with OC-46F2 or 
L19-IL2 as monotherapy. Furthermore, in the tumors recovered from mice treated 
with OC-46F2 either as monotherapy or in combination with L19-IL2, we observed 
a dramatic decrease of vascular density and loss of VM structures. These findings 
indicate for the first time a role of Syndecan-1 in melanoma VM and that targeting 
Syndecan-1, together with B-FN, could be promising in improving the treatment of 
metastatic melanoma.
INTRODUCTION
Building on the premise that blood vessels are 
essential for tumor growth and metastasis in all solid 
tumors, including melanoma, anti-angiogenic therapy was 
originally developed to “starve” primary and metastatic 
tumors by blocking blood vessel recruitment [1-6]. 
However, while anti-angiogenic drugs are effective at 
reducing angiogenesis, these therapies have not produced 
widespread or long lasting clinical benefits and have 
shown their limitations, due to many other mechanisms 
involved in tumor progression and regulated by the tumor 
microenvironment [3, 7-9]. 
Metastatic melanoma is one of the deadliest forms of 
cancer; progress in its treatment, however, is very limited 
[10-13]. Recently L19-IL2, an immunocytokine specific 
for the angiogenesis-associated B-fibronectin isoform 
able to selectively accumulate on tumor neovasculature, 
was investigated in a randomized phase II clinical trial in 
patients with metastatic melanoma in combination with 
dacarbazine or with L19-TNFα. Thus far, L19-IL2 has 
yielded encouraging results [10, 14-18].
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It is known that in many malignant tumors, 
including metastatic melanoma, other forms of blood 
supply in tumor tissues exist in addition to angiogenesis. 
One of these mechanisms is “vasculogenic” or “vascular” 
mimicry (VM), in which cells of a highly aggressive 
malignant tumor can form vascular-like channels without 
implicating endothelial cells, thereby providing nutrients 
for tumor growth [19, 20]. An emerging premise is that, in 
the cure of solid tumors, the most effective therapies will 
entail targeting combinations of factors for drug delivery. 
Markers of VM may therefore be important targets for this 
purpose [7-9, 20]. 
Many adhesion and membrane proteins, including 
MMP1/2, VEGFR-1/2, HIF-1, Nodal, FAK, EpHA2 
and VE-cadherin (CD144), seem to be crucial to VM 
formation in many types of solid tumors such as melanoma 
and glioma [20-24]. VE-cadherin, specifically expressed 
in endothelial cells, is also expressed in aggressive 
melanoma cells and its expression knockdown inhibits 
VM formation, thus making it a major candidate marker 
of VM [25]. Recent studies have also implicated some 
cancer stem cell (CSC) markers such as CD133, ALDH1 
and CD44 in VM formation [20].
Syndecan-1 (CD138), one of the four members of 
the syndecan family, is a cell surface heparan (HS) and 
chondroitin sulphate (CS) proteoglycan. Syndecan-1 
is expressed predominantly in epithelial cells [26], 
but it is also found in B lymphocytes at specific stages 
of differentiation [27]. More recently, it was shown to 
be expressed also in malignant melanoma cells [22]. 
Syndecan-1 expression correlates to increased metastatic 
potential in melanoma cells [28]. The structural features 
of the HS-chains are responsible for the interaction of 
Syndecan-1 with a number of soluble factors, including 
pro-angiogenic factors like Vascular Endothelial Growth 
Factor (VEGF) and Fibroblast Growth Factor-2 (FGF-
2), cell-associated molecules and extracellular matrix 
(ECM) components [26, 29, 30]. Furthermore, elevated 
levels of VEGF and shed Syndecan-1 form matrix-
anchored complexes that together activate integrin and 
VEGF receptors on endothelial cells, thereby stimulating 
tumor angiogenesis [31]. A number of findings suggest 
that Syndecan-1 is involved in the stimulation of CSC or 
tumor initiating cells (TIC) and that this can affect disease 
relapse and resistance to therapy [30] (and refs therein). 
We recently demonstrated that Syndecan-1 is a 
potential therapeutic target in melanoma and ovarian 
carcinoma. In fact, preclinical experiments of therapy 
in subcutaneous graft models of melanoma and ovarian 
carcinoma showed that scFv OC-46F2, specific for the 
ectodomain of Syndecan-1, inhibited vascular maturation 
and tumor growth [22]. 
In this study we demonstrate by in vitro and in vivo 
experiments that OC-46F2 antibody was able to inhibit the 
vascular mimicry of melanoma cells and vascular structure 
formation of endothelial cells. These findings indicate, for 
the first time, that Syndecan-1 is implicated in the process 
of vascular mimicry in melanoma. We report that OC-
46F2, administered systemically in combination with L19-
IL2, leads to a complete inhibition of tumor growth until 
day 90 from tumor implantation in 71% of treated mice. 
Moreover, at day 124 in the L19-IL2/OC-46F2 group, the 
tumor free survival was 64% in contrast to 0% observed in 
the L19-IL2 treated group. These results suggest that the 
combined therapy could improve the therapeutic efficacy 
of both OC-46F2 and L19-IL2 administered as single 
agents.
RESULTS
Characterization of human metastatic melanoma 
cells showing vasculogenic phenotype
We tested melanoma cell lines SKMEL28, MV3 
and melanoma cells isolated from ten patients, all 
positive for Syndecan-1, to form tubule-like structures 
on Matrigel. Moreover, the ability of all cell lines to 
induce tumor growth and lung metastasis when injected 
subcutaneously or in the tail vein of NOD SCID mice, 
respectively, was assessed. As summarized in Table 1, 
SKMEL28, MV3, MeTA and MeMO were able to form 
tubule-like structures on Matrigel, and six out of seven 
subcutaneously inoculated melanoma cells isolated from 
patients were able to induce tumor growth as SKMEL28 
cell line. Moreover, SKMEL28 and the two cell lines 
MeTA and MePA were able to metastatize to the lung after 
i.v. injections, as already described for the metastatic cell 
line MV3 [32]. To detect the human metastatic nodules we 
stained lung sections with the anti human Ki67 antibody 
that specifically recognizes human cells in proliferation 
(Supplementary Figure S1 A). Furthermore, we analyzed 
the c-Kit (CD117) expression and, in accordance with the 
literature [33], we observed that melanoma cells with a 
strong metastatic potential, such as SKMEL28, MePA, 
MeTA and MV3, were negative for c-Kit expression, 
in contrast to MeMI that expressed c-Kit (Table 1, 
Supplementary Figure S1 B and S2) and was unable to 
form metastases. We analyzed all melanoma cell lines for 
their expression of melanoma stem cell markers CD133/1 
and CD271 by cytofluorimetric analysis. While CD133/1 
was expressed only on MeTA, the majority of melanoma 
cell lines with vasculogenic phenotype were positive 
with CD271 (Supplementary Figure S2). Moreover, all 
melanoma cell lines expressed as mRNA other markers 
of cancer stem cells, such as CD44, ALDH1 and Nodal 
(data not shown).
We previously reported in Orecchia et al. 2013, 
that VEGFR-2 co-localized with Syndecan-1 in human 
melanoma xenograft. To investigate the role of VEGFR-2 
in the melanoma VM, we performed in vitro Matrigel 
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Table 1: Human metastatic melanoma cells characteristics associated to VM.
Figure 1: VEGFR-2 is involved in melanoma VM. A., In vitro Matrigel tube formation using melanoma cells SKMEL28 in presence 
of SU1498 (b) compared to untreated (a) or DMSO (c) treated cells. The differences in tubule formation were quantified by column bar 
graphs reported below the experiments. *** indicates extremely significant differences between treated and DMSO or untreated cells. 
Scale bars, 200 µm. The mean ± SEM are indicated. B., representative immunofluorescence of cryostat sections of SKMEL28/NOD SCID, 
stained with anti VEGFR-2 (a) and anti CD144 (b). Merged image shows co-localization of VEGFR-2 with CD144 (c). Scale bars, 10 µm.
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experiments with or without SU1498, a specific VEGFR-2 
kinase inhibitor using melanoma cells. As shown in Figure 
1A, SU1498 inhibits the in vitro formation of tubule-like 
structures (b) compared to treated with DMSO (c) or 
not treated (a) cells. Moreover, by immunofluorescence 
staining on SKMEL28/NOD SCID sections, we show that 
VEGFR-2 (Figure 1B, a) co-localizes with CD144 (Figure 
1B, b). 
We chose three representative melanoma cells 
from patients (MeMI, MePA and MeTA) and SKMEL28 
cell line and we observed that they were negative for 
the expression of human CD31, a marker of endothelial 
cells (Figure 2A and Supplementary Table S1), but that 
they expressed CD144 and VEGFR-2 (Figure 2B, 2C 
and Supplementary Table S1). These results indicate 
that tubular-like structures formed by melanoma tumor 
cells were not of endothelial origin. In Figure 2D, using 
OC-46F2, we show representative micrographs in which 
Syndecan-1 (CD138) co-localized with CD144 (a-c; g-i) 
and VEGFR-2 (d-f; l-n) in SKMEL28 and TIME cells. 
In Figure 3A, by immunofluorescence staining on 
SKMEL28/NOD sections, we show that OC-46F2 was 
able to recognize vessels of human origin. In fact, the same 
vessels were positive with CD144 antibody specific for the 
human protein as indicated by arrowheads. Moreover, we 
show that Syndecan-1 co-localizes with VEGFR-2. The 
same results were observed with staining on MeTA/NOD 
SCID sections. In human metastatic melanoma biopsies 
obtained from different patients (Figure 3B) the same 
co-localization of Syndecan-1 with CD144 or VEGFR-2 
was observed. All these results suggest that Syndecan-1 
is present in the same tubular like structures expressing 
CD144 and VEGFR-2 markers of VM.
Figure 2: Expression of human CD31, CD144 and VEGFR-2 in positive Syndecan-1 melanoma cells. A., Flow 
cytofluorimetric analysis of human CD31 expression in TIME endothelial cell and MeMI, MePA, MeTA and SKMEL28 human melanoma 
cells. Gray profiles represent negative controls. B., RT-PCR analysis of human Syndecan-1, CD144 and VEGFR-2 expression in MeMI, 
MePA, MeTA and SKMEL28 human melanoma cells. Beta-actin was used as positive control. Base pairs (b.p.) of human genes are 
indicated. C., Immunofluorescence analysis of TIME endothelial cells, SKMEL28 and MeTA human melanoma cells stained with anti-
CD144 or anti VEGFR-2 counterstained with DAPI. Scale bars, 20 µm. D., Immunofluorescence analysis of SKMEL28 human melanoma 
cells and TIME endothelial cells in which co-distribution of syndecan-1 (CD138) with CD144 or VEGFR-2 is shown. The merged signals 
are shown in the right panel (c, f, i, n). Scale bars, 10 µm. 
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Figure 3: Syndecan 1 co-localizes with CD144 and VEGFR-2 in melanoma tissues. Immunofluorescence analysis of cryostat 
sections of SKMEL28 and MeTA melanoma tumors in NOD SCID mice A. and of human metastatic melanoma from two patients B. double 
stained with OC-46F2 and anti-VEGFR-2 or anti-CD144 antibodies as indicated in each picture and counterstained with DAPI. The merged 
signals are shown in the right panel. Scale bars, 10 µm.
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Figure 4: Expression of Syndecan-1 in lung metastases. A., Immunofluorescence of cryostat sections of lung metastasis induced 
by i.v. MeTA injection in NOD SCID mice double stained with anti-human NuMA and OC-46F2, anti-VEGFR-2, anti-hCD31, anti-
hCD144 and anti mouse CD31 antibodies as indicated in each picture. Panel A (d-f) is counterstained with DAPI. Scale bars, 10 µm. B., 
qRT-PCR analysis of human Syndecan-1, VEGFR-2 and CD144 expression in human melanoma metastatic cells MeTA met in comparison 
to MeTA. 2-[∆][∆]Ct is reported in the column bar graph. *, **, indicate significant and very significant differences, between the two types 
of cells. C., Real time image of MeTA-GFP migration along endothelial tubules. Scale bars, 200 µm (a). Fluorescent staining of tubular 
structures growth on Matrigel using anti-GFP antibody to localize melanoma cells and anti-human CD31 antibody specific for endothelial 
cells (b-c). Scale bars, 50 µm.
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Human Syndecan-1, CD144 and VEGFR-2 
expression in experimental lung metastasis of 
human melanoma
To investigate the involvement of human 
Syndecan-1 in VM during the metastatic process, we 
performed immunofluorescence staining on lung sections 
of MeTA intravenously injected in NOD SCID mice. To 
specifically recognize all human melanoma cells, we used 
anti-human NuMA antibody and we observed a strong 
expression of Syndecan-1 (Figure 4A, a) and VEGFR-2 
(Figure 4A, b) in NuMA positive melanoma cells. These 
data correlate with the qRT-PCR results, in which we 
observed a significant increase of Syndecan-1 mRNA 
expression in MeTA human melanoma cells isolated 
from murine lung metastases (MeTA met) compared to 
injected cells, as seen for VEGFR-2 and CD144 (Figure 
4B). In Figure 4A we show, using OC-46F2 and anti 
human CD144 antibody (d-f), the presence of Syndecan-1 
Figure 5: OC-46F2 inhibits vascular mimicry and angiogenesis. A., SKMEL28 stably transfected cells with OC-46F2 were 
not able to form tubule-like structures after 48 hours from plated cells on Matrigel (b) in comparison to cells transfected with the empty 
vector (a) or with a control scFv (c) that formed well organized structures. B., in vitro Matrigel tube formation using MeTA melanoma cells 
(a-c) or SKMEL28 in presence of OC-46F2 and/or L19-IL2 in comparison to control scFv treated or untreated cells. C., in vitro Matrigel 
vascular channel formation using TIME endothelial cells (a-c) in presence of OC-46F2 and/or L19-IL2 in comparison to control scFv 
treated or untreated cells. The differences in tubule formation at different treatments were quantified by column bar graphs reported below 
the corresponding experiments. Symbols indicate statistically differences between the groups connected by lines: ns, not significant; *, 
significant; **, very significant and ***, **** extremely significant. Scale bars, 200 µm. The mean ± SEM are indicated. D., Photographs 
of plugs removed from OC-46F2 treated mice at different dose (a) and of representative plugs taken from untreated (n = 6), control scFv (n 
= 6) or OC-46F2 treated mice (n = 6) (b). 
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in tubule-like structures of human origin. All lung 
metastasis specimens were negative for human CD31 (c). 
Furthermore, the human tubule-like structures positive for 
OC-46F2 were negative for mouse CD31 (g-i). Figure 4C 
shows real time images of MeTA-GFP migration along 
endothelial tubules (a), and fluorescent staining, using 
anti-GFP and anti-human CD31 antibodies, illustrates the 
capacity of these tumor cells to localize along the external 
surface of vascular tubules, revealing a tropism for the 
vascular channels (b,c). 
Anti Syndecan-1 human recombinant antibody, 
OC-46F2, inhibits vascular mimicry and 
angiogenesis in in vitro and in vivo Matrigel 
experiments
To evaluate the capacity of OC-46F2 to inhibit 
vascular mimicry and angiogenesis, we performed in vitro 
experiments on Matrigel using SKMEL28, MeTA and 
TIME.
As shown in Figure 5A, SKMEL28 melanoma cells 
stably transfected with scFv OC-46F2 were not able to 
form tubule-like structures after 48 hours plated cells on 
Matrigel (b) in comparison to cells transfected with the 
empty vector (a) or with a control scFv (c) that formed 
well organized structures. A similar inhibitory effect of 
OC-46F2 was obtained by adding the antibody at the 
concentration of 200 µg/ml to the cells. In fact, the in 
vitro formation of tubule-like structures by SKMEL28 
and MeTA melanoma cells (Figure 5B) and of vascular 
structures by TIME endothelial cells (Figure 5C) was 
inhibited by scFv OC-46F2 (Figure 5B, b; 5C, b) 
compared to cells treated with control scFv (Figure 5B, c; 
5C, c) or not treated (Figure 5B, a; 5C, a). No inhibition 
or a slight reduction of vascular channel formation was 
observed by adding L19-IL2 to SKMEL28 melanoma 
cell line (Figure 5B, right column bar graph) or TIME 
endothelial cells (Figure 5C), respectively. Moreover, we 
evaluated the anti-angiogenic effect of OC-46F2 using in 
vivo Matrigel plug assay. Indications of an anti-angiogenic 
effect in response to different doses of OC-46F2 can be 
assessed visually because of the color difference in the 
plugs (Figure 5D, a). As shown in Figure 5D, b, the 
representative plug removed from OC-46F2 treated mice 
showed no FGF2-induced vascularization in contrast to 
plugs taken from control scFv treated or untreated mice. 
These results suggest that Syndecan-1 is involved in 
the tubule-like formation of melanoma cells and vascular 
structure formation of endothelial cells. Furthermore, 
since OC-46F2 recognizes an epitope of the core protein 
of Syndecan-1, as demonstrated in Supplementary 
Figure S3 by treating human melanoma cells with 
PNPX, an elongation inhibitor of protein-associated 
Figure 6: Immunofluorescence of cryostat sections of SKMEL28 melanoma tumors in NOD SCID mice double stained 
with OC-46F2 (a) and L19 (b) antibodies counterstained with DAPI. The merged signals show co-distribution of Syndecan-1 
with B-fibronectin in some vascular structures (c); in * and ** magnifications, some vessels were positive with OC-46F2 only, as indicated 
by white arrowhead (d-f and g-i). Scale bars, 200 µm (a-c) or 50 µm (d-i).
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glycosaminoglycan (GAG), it is conceivable that GAG 
chains of the molecule may not be implicated in these 
mechanisms.
Therapeutic efficacy of OC-46F2 in combination 
with L19-IL2 against human melanoma xenograft
We recently reported that the human recombinant 
antibody, scFv OC-46F2, specific for the ectodomain 
of Syndecan-1, exerts an antitumor activity in vivo 
by reducing tumor growth and vascular maturation in 
experimental human melanoma and ovarian carcinoma 
murine models [22]. In line with our already published 
data [15, 22] we confirmed that scFv OC-46F2 and 
L19, an scFv specific for the angiogenesis-associated 
B-fibronectin isoform, stain both ECM and tumor vessels 
(Supplementary Figure S4). Interestingly, in this study we 
observed that the anti Syndecan-1 antibody, OC-46F2, 
stained some intratumoral vessels that were negative 
with L19 antibody. In fact, as shown in the representative 
Figure 6 (a-c) and in its magnifications (d-f, g-i), both 
OC-46F2 and L19 stain the majority of the vessels in the 
experimental human melanoma SKMEL28; however some 
vessels were positive with OC-46F2 only (see arrowheads 
in Figure 6, d-f, g-i). 
To investigate if a combined therapy with another 
drug, able to selectively localize to the tumor structures, 
could enhance the antitumor effect of scFv OC-46F2, we 
chose L19-IL2, an immunocytokine composed of human 
scFv L19 and IL2 [16, 34, 35]. 
Combination therapy experiments were performed 
in NOD SCID mice bearing SKMEL28 human melanoma. 
In a preliminary experiment, the doses used were 40 µg 
for OC-46F2 and 40 µg for L19-IL2 immunocytokine 
(given in combination) for each administration. The 
combination schedule of therapy is described in Materials 
and Methods and summarized in Figure 7A. As shown in 
Figure 7B until day 35 from melanoma cell subcutaneous 
implantation we observed a drastic reduction of tumor 
growth in 100% of mice compared to the untreated 
control group. From day 39, six out of thirteen mice (40%) 
presented an increase of tumor volume; therefore a second 
cycle of combined therapy was administered following the 
combination schedule reported in Figure 7A. As shown 
in the upper right side of the Figure 7B, in all six treated 
mice the tumor volumes decreased from day 49 to day 
56 when mice received OC-46F2 only. The remaining 
seven out of thirteen mice (60%) received no treatment. 
The two-tailed p value of the two groups at day 46 and 49 
from tumor implantation was very significant (p value = 
0.0058) and significant (p value = 0,0192), respectively. In 
this preliminary experiment the group of mice treated with 
the combined therapy shows a delay of 60 days of tumor 
growth respect to the control group that did not receive 
any therapy. A second experiment was carried out using 
a larger number of mice (n = 24) in order to have three 
groups that would receive a second cycle of therapy as 
follows: L19-IL2 and OC-46F2 as single therapy or in 
combination. Moreover, because OC-46F2 is completely 
non-toxic, we increased the dose of OC-46F2 to 80 µg 
(high dose, HD), leaving the dose of L19-IL2 unchanged 
due to its toxicity. As shown in Figure 7C groups of mice 
were untreated or treated with OC-46F2, L19-IL2 as single 
therapy or combination therapy. The combination therapy 
(HD) completely inhibited tumor growth until day 90 in 
seventeen out of twenty four treated mice (71%). From 
day 32 the two-tailed p value of L19-IL2/OC-46F2 high 
dose group compared to OC-46F2 and L19-IL2 groups 
of mice was extremely significant (p < 0.0001) and very 
significant (p = 0.0037), respectively, indicating the strong 
efficacy of combined therapy (Figure 7C). In fact, at day 
124 in the L19-IL2/OC-46F2 high dose group, the tumor 
free survival was 64% compared to 0% in L19-IL2 treated 
group (Figure 7D). To microscopically analyze tumor 
sections following combination treatments, the experiment 
was interrupted at day 140 when the tumor volumes were 
between 0.8 and 1.6 cm3. None of the groups exhibited a 
body weight loss greater than 3% at any time point during 
the treatments. The seven not completely responding 
mice out of twenty four (29%) were randomized into 
three groups and subjected to a second cycle of therapy, 
as reported previously, following the treatment schedule 
described in Figure 7A for the mono- and combined 
therapy. A delay in tumor growth was observed in the 
group in which the two molecules were administered 
together (Supplementary Figure S5). 
Figure 8A-C shows a drastic reduction of vessel 
numbers in tumors from mice that received OC-46F2 
either as monotherapy or combination therapy, as revealed 
using anti-Desmin and anti-SMA antibodies, markers 
of early and mature vessels, respectively. Moreover, 
the expression of the two VM markers, VEGFR-2 and 
CD144, was almost negative in the tumors from animals 
receiving OC-46F2 therapy (Figure 8 D). These in vivo 
experiments evaluating the change in vascular density 
and VM structures in the tumor tissues taken from treated 
mice confirm the efficacy of OC-46F2 in VM inhibition as 
above reported in in vitro results. 
DISCUSSION
Poor five-year survival has been observed in some 
VM-forming aggressive cancers, including melanoma. 
Furthermore, a higher rate of VM has been reported 
in melanoma patients with metastasis compared to 
patients with primary melanoma, indicating that VM 
is able to promote tumor metastasis [20, 36]. Recently 
accumulating research focuses on the availability of new 
anticancer treatments able to inhibit the formation of VM 
that could be combined with anti-angiogenic therapies. 
Thalidomide, one of the few anti-angiogenic agents that 
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Figure 7: Targeting Syndecan-1 by scFv OC-46F2 enhances the therapeutic efficacy of immunocytokine L19-IL2 in 
melanoma. A., Administration schedule of OC-46F2 and L19-IL2 as single or combined treatments. Reported days are from tumor cells 
s.c. implantation. LD, Low Dose; HD, High Dose. Combination therapy experiments were started eight days after SKMEL28 human 
melanoma implantation in NOD SCID mice, when palpable tumors had developed. Mice were randomized in the different treatment 
groups. B., Tumor growth inhibition in mice (n=13) treated with L19-IL2 and OC-46F2 low dose administered in combination for eighteen 
days. In the upper right side a magnification of growth curve from day 39 is reported. Only 40% of mice (n = 6) were subjected to a second 
cycle of combination therapy of OC-46F2 every day for eight days and L19-IL2 on days 40, 43, 46 as indicated by the arrows. * and ** 
indicate significant and very significant differences, respectively, between the group treated with second cycle and untreated group at days 
46 and 49. C., Tumor growth inhibition in mice (n=24) treated with L19-IL2 and OC-46F2 at high dose administered as monotherapy or in 
combination. ** indicates very significant difference between the OC-46F2 treated and untreated groups at days 27 and 35. From day 32 the 
two-tailed p value of L19-IL2/OC-46F2 high dose group of mice compared to OC-46F2 and L19-IL2 groups was extremely significant (p 
< 0.0001, ****) and very significant (p = 0.0037, **), respectively. The mean tumor volumes ± SEM are indicated. Statistical significance 
of the differences between the groups was evaluated by nonparametric Mann Whitney test. D., Tumor free survival curves versus time 
(days) of SKMEL28 melanoma bearing mice treated with L19-IL2 as monotherapy, L19-IL2 and OC-46F2 HD as combination therapy or 
untreated. Arrowheads indicate the OC-46F2 treatment administrated every day in the reported range of days. Arrows indicate the L19-IL2 
treatment administrated in the reported days.
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had shown efficacy in suppressing VM channels and 
mosaic vessel formation in an experimental model of 
melanoma, was never used in clinical applications due 
to its severe teratogenic effects [37]. Moreover, some 
anti-angiogenic agents, such as the monoclonal antibody 
bevacizumab, or endostatin and TNP-470, had no effect on 
VM; others, such as sunitinib, accelerate tumor cell VM in 
triple-negative breast cancer [23, 38-40]. The spectrum of 
therapeutic options for the cure of patients with advanced 
melanoma continues to expand, and a new anti-angiogenic 
drug, the immunocytokine L19-IL2, has been used in 
experimental phase II clinical trials for this deadly form 
of cancer [10, 14-18]. 
We recently reported that blocking Syndecan-1 
activity via the human specific antibody scFv OC-
46F2 leads to an antitumor effect by inhibiting vascular 
maturation and tumor growth in experimental human 
melanoma and ovarian carcinoma models [22]. In 
this study we observed that VM of melanoma cells 
was inhibited by SU1498, a specific VEGFR-2 kinase 
inhibitor, as demonstrated in glioblastoma cell lines [23]. 
Our results are consistent with our previously reported 
Figure 8: Therapeutic treatment with OC-46F2 inhibits vascular maturation and induces loss of VM structures. 
Quantification of A. immature blood vessels (Desmin staining) and B. mature blood vessels (SMA staining) per HMMF in SKMEL-28 
tumors subjected to different types of treatments. The mean ± SEM are indicated. *** indicates extremely significant differences between 
OC-46F2 or L19-IL2/OC-46F2 HD treated and untreated groups. n.s. indicates not significant differences between L19-IL2 treated and 
untreated groups. Immunofluorescence analysis of cryostat sections of tumors recovered from SKMEL28/NOD SCID mice subjected to the 
different type of treatments stained with anti-desmin or anti-SMA C. and anti-VEGFR-2 or anti-CD144 D. antibodies as indicated in each 
picture and counterstained with DAPI. Scale bars, 50 µm.
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data and with many reports which describe an interaction 
between Syndecan-1 and VEGFR-2 [22, 23, 41, 42]. 
However, other VEGF receptors could be involved in VM, 
as recently reported for VEGFR-1 [24]. We demonstrated 
that Syndecan-1 positive melanoma cell lines having a 
vasculogenic and a stem cell-like phenotype, express two 
molecules involved in melanoma VM, such as CD144 
and VEGFR-2 [20, 43]. Moreover, all these cell lines are 
negative with anti-CD31, differently from Dunleavey et 
al., who described a subpopulation of melanoma cells 
positive for CD31 but negative for VEGFR-2 [44]. We 
observed an increased Syndecan-1 mRNA expression 
in human melanoma cells isolated from murine lung 
metastases (MeTA met) compared to the injected cells 
(MeTA). Analyzing lung metastatic tissues we have 
shown that Syndecan-1 is expressed in the early stage 
of metastatic development, similarly to VEGFR-2 and 
CD144. Furthermore, the in vitro and in vivo experiments 
have shown that the antibody OC-46F2 was able to inhibit 
human melanoma VM and to block the pro-angiogenic 
activity of Syndecan-1. 
In a comparative study of Syndecan-1 and 
angiogenesis-associated B-fibronectin isoform expression 
in melanoma tissues, using OC-46F2 and L19 antibodies, 
respectively, we observed that some vessels were positive 
with the anti-Syndecan-1 antibody but negative with L19. 
These preliminary observations afforded the possibility to 
investigate the effectiveness of OC-46F2 in combination 
with the L19-IL2 immunocytokine in preclinical 
therapeutic experiments. Furthermore, the use of a human 
melanoma cell line in immune-compromised NOD SCID 
mice allowed us to study the human or murine origin 
of tumor vessels and to verify the efficacy of the two 
treatments specific for different targets of tumor stroma. 
We found that the combination therapy using the 
OC-46F2 anti Syndecan-1 blocking antibody and the 
immunocytokine L19-IL2 leads to a complete inhibition 
of tumor melanoma growth until day 90 from tumor 
implantation in 71% of treated mice. A second cycle 
of combined therapy in the not completely responding 
mice was efficacious to induce a further delay in tumor 
growth. Moreover, by monitoring mice for a longer time, 
we observed that at day 124, the tumor free survival was 
64% in the L19-IL2/OC-46F2 high dose group compared 
to 0% observed in L19-IL2 treated group. The analysis 
of tumor tissues taken from mice treated with OC-46F2 
as monotherapy or combination therapy confirms that the 
anti Syndecan-1 antibody inhibits vascular maturation and 
induces loss of VM structures. 
These results suggest that the combined therapy 
could improve the therapeutic efficacy of L19-IL2 and 
OC-46F2 administrated as monotherapy, and that OC-
46F2 may be administered at high dose without any toxic 
effect. On the basis of these results, it will be interesting 
to extend the preclinical experiments of combined therapy 
to a model of human melanoma cells generated from 
patients. 
In conclusion, these findings indicate for the first 
time the involvement of Syndecan-1 in the process of  VM 
in metastatic melanoma. Blocking Syndecan-1 activity by 
OC-46F2 antibody in combination therapy with L19-IL2 
could result in potential novel therapeutic approaches 
for metastatic melanoma. Moreover, our data are in line 
with the observation that the most effective therapies 
should target different factors involved in the mechanisms 
responsible for tumor progression. 
MATERIALS AND METHODS
Cell lines and human tissues
Cultures of primary human melanoma cells MeTA, 
MeMO, MeMI, MePA, MeOV, MeCoP, MeFeR, MeBO, 
MeTU, MeDeBo [45], human metastatic melanoma MV3 
cell line from S. Ferrone (New York Medical College), 
human melanoma SKMEL28 (ATCC, Rockville, MD) 
were grown in RPMI 1640 supplemented with 10% FBS 
and 2% L-glutamine. The telomerase-immortalized human 
microvascular endothelium cell line, TIME (ATCC), was 
grown in Endothelial Cell Basal Medium-2 (EBM-2) 
which is supplied as part of the Microvascular Endothelial 
Cell Growth Medium-2 bullet kit (EGM-2-MV) available 
from Lonza/Clonetics Corporation (Basel, Switzerland). 
All cell lines were grown at 37°C in a 5% CO2 incubator. 
All cell lines were used within six months of resuscitation.
MeTA met were isolated from murine lung 
metastasis and cultured in RPMI 1640 supplemented with 
10% FBS and 2% L-glutamine until 100% of cells were 
positive with the specific anti human Ki67 antibody and 
tested by immunofluorescence.
Human metastatic melanoma tissues used in 
immunofluorescence analyses were obtained in accordance 
with informed consent procedures approved by the internal 
Ethics Board of the National Cancer Institute (IRCCS S. 
Martino-IST, Italy). 
Flow cytofluorimetric analysis
For indirect one-colour cytofluorimetric analysis, 
cells were stained with scFv OC-46F2 (5 µg/ml) mixed 
with mouse monoclonal antibody immunoglobulin IgG1 
anti-Myc 9E10 (2.5 µg/ml) (ATCC, Rockville, MD) or the 
mouse IgG1 anti-human CD31 (M0823, DAKO, Glostrup, 
Denmark). PE conjugated isotype specific goat anti-
mouse IgG1 (Life Technologies) was used as secondary 
antibody. Melanoma cell lines SKMEL28 and MV3 were 
incubated overnight in presence or absence of 5-10 µg/ml 
of p-Nitrophenyl-beta-D-xylopyranoside (PNPX) (Sigma) 
[46]. The day after the expression of Syndecan-1 was 
highlighted by cytofluorimetric analysis using OC-46F2 
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or B-A38 (10-520-C100, Exbio, Czech Republic). Anti-
CD133/1 (AC133) pure, PE-conjugated anti-c-Kit/CD117 
(AC126-PE), anti-p75 neurotrophin receptor (NTR)/
CD271-PE mAbs and their isotype-matched controls 
were purchased from Miltenyi Biotec GmbH (Bergisch 
Gladbach, Germany). PE-conjugated goat anti-mouse 
IgG1 mAb was purchased from Southern Biotechnology 
Associated (Birmingham, AL, USA). 
RT-PCR and qRT-PCR
Total RNA was extracted from human melanoma 
cells harvested using RNAeasy mini kit (Qiagen). 
RealMasterScript SuperMix Kit (5 Prime) was used to 
generate cDNA. Amplifications were performed for 30 
cycles (30 s at 95°C, 30 s at 58°C, 30 sec at 72°C) for 
all genes except for Syndecan-1 and Nodal, performed 
for 35 cycles, and CD144, performed for 40 cycles using 
Platinum TAQ (Life Technology). PCR products were run 
on a 1.5% agarose gel and visualized by ethidium bromide 
staining. A SybrGreen-based kit (Invitrogen) was used for 
Real Time PCR. Primers specific for human genes are 
reported in Supplementary Table S2.
Purification and characterization of human 
recombinant antibody OC-46F2 and 
immunocytokine L19-IL2
The scFv OC-46F2, the immunocytokine L19-IL2 
and their controls were purified from the conditioned 
media of mammalian cells expressing proteins using 
affinity columns and characterized as previously described 
[22, 34]. Particularly, the OC-46F2 scFv and its control 
were purified on a ProteinA/Sepharose column (GE 
Healthcare) according to the manufacturer’s instructions. 
The immunocytokine L19-IL2 was purified on ED-B 
fibronectin domain [47] conjugated to Sepharose 4B (GE 
Healthcare). Proteins were dialyzed against phosphate 
buffer saline (PBS) overnight at +4°C and sterile 
filtered using Millex-GP 0.22 µm filter unit (Millipore). 
Subsequently, they were analyzed under reducing 
conditions by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and in native conditions by 
fast-protein liquid chromatography on a Superdex 200 
column (Supplementary Figure S6).
In vitro tubules formation assay
Glass coverslips in 24-well cell culture plates were 
pre-coated with reduced growth factor Matrigel at the 
concentration of 18 mg/ml (354263, Corning, Bedford, 
US) and incubated for 30 minutes at 37°C. Melanoma 
cells and endothelial cells were transferred at the density 
of 4x104 or 9x104 cells per well in complete specific 
medium, respectively, incubated at 37°C 5% CO2 and 
then were observed for their capacity to form tubule-like 
structures or vascular tubules.
To test the ability of scFv OC-46F2 to inhibit tubule 
formation by melanoma cell lines SKMEL28 transfected 
with empty vector pcDNA3.1 or scFv OC-46F2 or control 
scFv [22] were plated on Matrigel in complete specific 
medium and incubated at 37°C 5% CO2 for 48 hours. 
Moreover, OC-46F2 or control scFv and L19-IL2 were 
added at the concentration of 200 µg/ml after four to six 
hours when SKMEL28, MeTA and TIME started to form 
tubules [19]. All experiments were performed in triplicate. 
After fixation in 2% paraformaldehyde in PBS, the tubules 
formed were counted on ten different high magnification 
microscopic fields per coverslip under light microscopy 
(Leica Microsystems, Wetzlar, Germany) at 100X or 
50X magnification for melanoma and endothelial cells, 
respectively. Images were captured using a DM LB2 
microscope camera (Leica).
Endothelial cell and melanoma cell co-culture on 
matrigel
Glass coverslips in 24-well cell culture plates were 
pre-coated with reduced growth factor Matrigel at the 
concentration of 18 mg/ml (354263) and incubated for 
30 minutes at 37°C. TIME were transferred at the density 
of 1x105cells per well in complete specific medium and 
incubated overnight at 37°C 5% CO2. The day after tubule 
formation, MeTA-GFP (4x104cells/well) were added 
and real time images were analyzed with an inverted 
microscope. After four hours, we performed fixation in 
2% paraformaldehyde in PBS and immunofluorescence 
analysis.
In vivo matrigel plug assay for angiogenesis
C57BL6/J male mice (Charles River Laboratories 
International,Wilmington, MA, USA) were 
subcutaneously injected with 500 µl of reduced growth 
factor Matrigel phenol red free (356231, Corning) at the 
concentration of 10 mg/ml supplemented with 300 ng/ml 
FGF2 and 30UI/ml Heparin in absence or presence of 100, 
200, 400 or 600 µg/mouse of scFv OC-46F2 or control 
scFv. After four days the animals were killed and the plugs 
removed [48, 49]. 
Immunofluorescence and immunohistochemistry
For immunofluorescence staining, tumors or lungs 
were excised, embedded in cryo embedding medium 
(Kaltek, Italy) and stored at -80°C. Cryostat sections 
(6µm) of tumors were fixed in ice-cold acetone for 10 
minutes and dried at room temperature. Cells were plated 
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on glass coverslips in a 24-well cell culture plate in 
complete medium and were grown at 37°C in a 5% CO2 
incubator. Cells were fixed in 2% paraformaldehyde in 
PBS for 30 minutes and permeabilized in 0,1% Triton in 
PBS for 10 minutes.
For immunofluorescence we used scFv OC-46F2 
(at the concentration of 5µg/ml) mixed with anti-Myc (at 
the concentration of 1.25 µg/ml), the rat anti-mouse CD31 
(clone MEC 13.3, kindly provided by A. Mantovani, 
Humanitas Institute, Milan, Italy), the mouse IgG1 anti-
human CD31, the rabbit polyclonal anti-VEGF receptor-2 
(ab2349, Abcam, UK), the mouse IgG2b anti human-
CD144 (MAB9381, R&D Systems, Minneapolis, USA), 
the human L19IgG1 anti B-fibronectin [15], the goat 
anti human NUMA (sc-18557, Santa Cruz, Texas, USA), 
the chicken polyclonal anti-GFP (ab13970, Abcam), the 
mouse anti human ki-67 (M0722, Sigma-Aldrich), the 
mouse anti-human smooth muscle actin (SMA) (DAKO) 
and the rabbit polyclonal anti-desmin (Abcam). As 
secondary antibody we used the Alexa Fluor 350, 488 or 
594 goat anti-mouse IgG1 for anti-Myc and anti-human 
CD31, the Alexa Fluor 594 goat anti-rat for anti-mouse 
CD31, the Alexa Fluor 594 goat anti rabbit for anti-VEGF 
receptor-2, the Alexa Fluor 594 goat anti-mouse IgG2b for 
anti human-CD144, the Alexa Fluor 594 chicken anti goat 
or the Alexa Fluor 350 donkey anti goat for anti-Numa, 
the Alexa Fluor 488 goat anti chicken for anti-GFP and 
the Alexa Fluor 488 or 594 goat for L19IgG1, the Alexa 
Fluor 594 goat anti-mouse IgG2a for anti-SMA and the 
Alexa Fluor 594 goat anti rabbit for anti-desmin (Life 
Technologies, USA). The tissue sections or cells were 
counterstained with DAPI using ProLong® Gold Antifade 
Mountant (Life Technologies) or Glycer gel (DAKO). 
Images were captured using a ApoTome microscope 
with AxioCam (Karl Zeiss, Thornwood, NY, USA). The 
immunohistochemical procedures have been described in 
Orecchia et al. [22]. 
Animal experimental models
Six-week-old female NOD SCID mice were 
originally obtained from the Charles River Laboratories 
International (Wilmington, MA, USA) and were bred 
in-house. Housing, treatment and sacrifice of animals 
followed national legislative provisions (Italian law no. 
116, 1992 and no. 26, 2014) for the protection of animals 
used for scientific purposes. 
Six-week-old female NOD SCID mice were 
subcutaneously (s.c.) injected with 5x106 SKMEL28, 
MeTA, MeMO, MeMI, MePA, MeOV, MeCoP and 
MeFeR melanoma cells and the tumor growth was 
monitored daily. Specimens of SKMEL28 and MeTA 
human melanoma were obtained by subcutaneous 
injection of 107 cells/mouse in NOD SCID mice. Animals 
were sacrificed when tumors reached a volume of about 
1.0 cm3. 
Six-week-old female NOD SCID mice were injected 
intravenously (i.v.) with the human melanoma MV3, 
SKMEL28, MeTA, MeMI, MePA cell lines (1.5x106 cells/
mouse). Eighteen days following the i.v. injection of MV3 
cells and 45 days following the i.v. injection of other cell 
lines, mice were sacrificed and lungs were harvested.
In vivo treatments with purified OC-46F2 or 
immunocytokine L19-IL2 as monotherapy or combination 
therapy were performed in NOD SCID mice each s.c. 
injected with 107 SKMEL28 human melanoma cells. 
When tumors were palpable, mice were randomized in 
the different treatment groups. In vivo treatments with 
purified OC-46F2 [22] or immunocytokine L19-IL2 [34] 
as monotherapy or combination therapy were performed 
in NOD SCID mice each s.c. injected with 107 SKMEL28 
human melanoma cells. When tumors were palpable 
different types of therapy were started.
For monotherapy, two groups of eight mice each 
received 80 µg scFv OC-46F2 every day from day eight 
to day twenty five by s.c. injection into the tail vein of 
each animal and 40 µg L19-IL2 every three days from day 
nine to day twenty one by s.c. injection into the tail vein 
of each animal, respectively. Similar groups of animals 
were untreated. For the first cycle of combined therapy 
with low dose (LD) or high dose (HD) OC-46F2, two 
groups of thirteen or twenty four mice were injected with 
40 µg or 80 µg of OC-46F2, respectively, together 40 µg 
L19-IL2 following the same scheme of monotherapy. For 
the second cycle of combined therapy six mice of the 
LD group and three mice of the HD group were injected 
with 40 µg or 80 µg of OC-46F2, respectively, every day 
from day thirty-nine to day fifty-six day by s.c. injection, 
together 40 µg L19-IL2 on days forty, forty-three and 
forty-six into the tail vein of each animal. For the second 
cycle of monotherapy in the HD group we followed the 
same scheme for combined therapy using OC-46F2 and 
L19-IL2 separately. On days in which both molecules were 
administered, OC-46F2 was injected into the peritoneum 
after six hours from L19-IL2 injection into the tail vein. 
Every day from tumor cell implantation, the tumor 
volumes were determined using the following formula: 
(d)2 x D x 0.52, where d and D are the short and long 
dimensions (centimeters) of the tumor, respectively, 
measured with a caliper. The animals’ weight was recorded 
daily. Animals were sacrificed when the tumor volume 
reached a volume between 0.8 and 1.6 cm3 and tumors 
were stored at -80°C. 
Statistical analysis
All results are presented as mean ± SEM. Statistically 
significance of the differences between the groups was 
evaluated by nonparametric Mann Whitney test using 
Prism 6 for MAC. 
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